Prescription Price Comparison for a Chronic-Condition Niche
Cost-driven medication non-adherence is a real and well-documented problem — KFF and CDC survey data consistently put self-reported cost-related non-adherence around 1 in 4 to 1 in 5 adults, concentrated in chronic conditions like diabetes and autoimmune disease. But the price-comparison layer of this problem is already owned by GoodRx, a publicly traded company with roughly 20 million monthly users and direct integrations at most U.S. pharmacy counters, plus well-funded challengers SingleCare and Mark Cuban's Cost Plus Drugs. The only defensible entry point is not comparing prices generically — it's picking one or two chronic-condition drug classes and pairing price comparison with hands-on patient-assistance-program (PAP) enrollment, which none of the big three do as a white-glove service. This is a lifestyle-income niche play, not a venture-scale one.
This is a hard one to recommend without heavy caveats. GoodRx alone processes price comparisons for the vast majority of U.S. cash-pay prescriptions and has spent over a decade and hundreds of millions of dollars building pharmacy-side integrations a solo builder cannot replicate. Anyone entering generic 'compare drug prices' territory is fighting a category-defining incumbent plus two other well-capitalized players. The only honest path in is a narrow wedge: pick one chronic-condition community, become the best resource anywhere for that community's specific assistance programs, and monetize through affiliate links plus a paid enrollment-help tier. Treat this as a content-and-service micro-business capped at a few thousand dollars a month, not a scalable startup.
The wedge that works is depth, not breadth: manufacturer patient-assistance programs (e.g., Eli Lilly's Insulin Value Program, various biologic manufacturer copay cards) have eligibility rules, income thresholds, and paperwork that change yearly and that GoodRx's self-serve interface does not walk users through. A concierge who tracks one drug class closely and personally helps people apply can charge $30-$75 per successful enrollment or a small monthly membership, while still linking out to GoodRx/SingleCare coupons as an affiliate for the transactional price-comparison piece. Revenue is capped by the size of the chosen niche, so this only works picking a condition with a large enough patient population (diabetes, MS, rheumatoid arthritis) to sustain traffic.
Slight uptick Sept-Dec as insurance plans reset deductibles and people search for year-end drug cost help.
Suits you if
- ✓You have direct experience in pharmacy, PBM operations, or patient assistance program administration
- ✓You're willing to go deep on one drug class rather than build a broad comparison tool
- ✓You're comfortable with affiliate-revenue economics rather than a subscription SaaS model
- ✓You can write and maintain detailed, accurate program-eligibility content that changes yearly
Skip it if
- ✕You want to compete broadly on 'compare any drug price' — GoodRx already won that
- ✕You expect to raise investment or build toward a large exit
- ✕You're not willing to personally help people through PAP applications (the paid tier depends on this)
- ✕You don't have healthcare-adjacent credibility to earn trust with a vulnerable audience
Skills: Requires real familiarity with how patient assistance programs work — income verification, manufacturer copay card rules, 340B pricing — plus enough web skills to run a simple content site with affiliate links and a lightweight intake form. Comfort writing empathetic, plain-language healthcare content matters more than technical skill here.
Unlock this idea
Get the full step-by-step plan, tools list, and experience breakdown with lifetime access to the whole database.
Get full access